CD58 acts as a tumor promotor in hepatocellular carcinoma via activating the AKT/GSK-3β/β-catenin pathway

Table 3 Correlation between CD58 expression in tumor tissues and clinicopathological factors of 69 patients in HCC

Clinicopathological factors	CD58-High (n = 43)	CD58-Low (n = 26)	p value
Age
≥ 60	38	10	< 0.0001***
< 60	5	16	< 0.0001***
Sex
Male	40	8	< 0.0001***
Female	3	18	< 0.0001***
Tumor size
> 5 cm	22	7	0.0481*
≤ 5 cm	21	19	0.0481*
Differentiation level
Low/Middle	38	18	0.0488*
High	5	8	0.0488*
AFP (μg /L)
< 400	29	19	0.6220
≥ 400	14	7	0.6220
Satellite focus
With	13	5	0.3132
Without	30	21	0.3132
Tumor thrombus
With	23	7	0.0313*
Without	20	19	0.0313*
Liver cirrhosis
With	15	16	0.7645
Without	28	10	0.7645
Chronic hepatitis
With	14	18	> 0.8772
Without	29	8	> 0.8772

ISSN: 1479-5876